A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of
single and repeat doses of rhuMAb IFNalpha, administered through the SC or IV route, in
adults with Systemic Lupus Erythematosus.